LYZL1 Regulates MHC and Promotes Immune Response in Cancer Cells

Target Name: LYZL1

NCBI ID: G84569

LYZL1

LYZL1 Regulates MHC and Promotes Immune Response in Cancer Cells

LYZL1 (MGC33408), a protein located in the major histocompatibility complex (MHC), is a key regulator of cell surface antigens and has been identified as a potential drug target in the field of cancer. MHC is a protein complex that is found in the cell nucleus and is responsible for presenting antigens from the body's immune system to T-cells. LYZL1 plays a crucial role in the regulation of MHC expression and has been shown to be involved in the immune response.

Research has shown that LYZL1 is a key regulator of MHC class I molecules, which are the major antigens that the immune system recognizes as foreign. MHC class I molecules are composed of a large protein complex that includes several subunits, including the major histocompatibility complex ( MHC) alpha chain, which is the protein that is targeted by LYZL1. LYZL1 is responsible for the stability and complexation of MHC alpha chain subunits, which are critical for its function.

LYZL1 has also been shown to play a role in regulating MHC class II molecules, which are the antigens that the immune system recognizes as self. MHC class II molecules are composed of a smaller protein complex that includes several subunits, including the major histocompatibility complex ( MHC) beta chain, which is the protein that is targeted by LYZL1 in MHC class II molecules. LYZL1 is responsible for the stability and complexation of MHC beta chain subunits, which are also critical for its function.

The regulation of MHC molecules by LYZL1 is critical for the immune response. During the immune response, LYZL1 helps to ensure that the immune system recognizes foreign antigens and does not recognize self-antigens. This is important because if the immune system attacks the body's own cells or tissues, it can lead to diseases such as cancer.

LYZL1 has also been shown to play a role in the regulation of cellular processes that are critical for the survival of cancer cells. For example, LYZL1 has been shown to regulate the production of cell cycle proteins, which are proteins that help to control the cell's division. This is important because the production of cell cycle proteins is critical for the growth and survival of cancer cells.

In addition, LYZL1 has also been shown to play a role in the regulation of cellular processes that are critical for the development and progression of cancer. For example, LYZL1 has been shown to regulate the production of pro-inflammatory cytokines, which are proteins that help to promote the growth and survival of cancer cells. This is important because the production of pro-inflammatory cytokines is critical for the development and progression of cancer.

LYZL1 has also been shown to play a role in the regulation of cellular processes that are critical for the regulation of cell death. For example, LYZL1 has been shown to regulate the production of cell death proteins, which are proteins that help to cause cell death . This is important because the regulation of cell death is critical for the survival of cancer cells.

LYZL1 has also been shown to play a role in the regulation of the immune response. For example, LYZL1 has been shown to regulate the production of immune checkpoint proteins, which are proteins that help to protect cancer cells from the immune system. This is important because the regulation of the immune response is critical for the survival of cancer cells.

In conclusion, LYZL1 is a protein that plays a crucial role in the regulation of MHC and

Protein Name: Lysozyme Like 1

The "LYZL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LYZL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets